AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Prolyl 3-hydroxylase OGFOD1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8N543

UPID:

OGFD1_HUMAN

Alternative names:

2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1; Termination and polyadenylation 1 homolog; uS12 prolyl 3-hydroxylase

Alternative UPACC:

Q8N543; H3BUQ2; Q9H7U5; Q9H9J9; Q9HA87; Q9HCG0; Q9NVB6

Background:

Prolyl 3-hydroxylase OGFOD1, also known as 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1, plays a crucial role in protein synthesis. It specifically catalyzes the 3-hydroxylation of 'Pro-62' in the small ribosomal subunit uS12 (RPS23), a process vital for regulating translation termination efficiency. Additionally, OGFOD1 is implicated in stress granule formation, highlighting its significance in cellular stress responses.

Therapeutic significance:

Understanding the role of Prolyl 3-hydroxylase OGFOD1 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes such as protein synthesis and stress response underscores its potential as a target for drug discovery, aiming to modulate these pathways in disease contexts.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.